Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Investors are still underrating this insurance disrupter.
The latest trading day saw Oscar Health, Inc. (OSCR) settling at $28.26, representing a -2.25% change from its previous close.
Oscar Health (OSCR) has been back on investors’ radar after a sharp stock rally following its business update at the Goldman Sachs Healthcare Conference, where management reaffirmed full-year 2026 guidance and highlighted favorable utilization trends. See our latest analysis for Oscar Health. The stock’s rally around the Goldman Sachs Healthcare Conference and upbeat commentary on utilization trends come on top of very strong momentum, with a 90 day share price return of 118.52% and a 1 year...
Is OSCR a good stock to buy? We came across a bullish thesis on Oscar Health, Inc. on Deep Value Returns’s Substack. In this article, we will summarize the bulls’ thesis on OSCR. Oscar Health, Inc.’s share was trading at $27.22 as of June 9th. Oscar Health, Inc. operates as a healthcare technology company in the United […]
Capital continued to flow toward companies with visible execution and growth opportunities.
Oscar Health shares rally on a bullish Barclays’ research note. Here’s how high the investment firm believes OSCR stock could fly in 2026.
Barclays upgraded its rating of Oscar to overweight, a buy equivalent, and reiterated its overweight rating on Centene in a new research note.
Shares of health insurance company Oscar Health (NYSE:OSCR) jumped 10.8% in the afternoon session after the company provided a business update and reaffirmed its full-year 2026 guidance during a presentation at the Goldman Sachs Healthcare Conference.
Despite ACA market challenges and exits by Cigna and Aetna, Oscar sees competitor withdrawals as a potential opportunity for growth in 2027.
Oscar Health, Inc. recently amended and restated its employment agreement with co-founder Mario Schlosser as he moved from President of Technology and Chief Technology Officer to Co-Founder & Advisor to the CEO, effective June 1, 2026, while he continues to support the company’s artificial intelligence and digital health agenda and remains on the Board. At the same time, a major Wall Street firm upgraded its view on Oscar Health after Q1 2026 results exceeded expectations and reinforced...
Wells Fargo raises price target on Oscar Health stock to $20. Here’s why the bank turned bullish on OSCR shares.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Oscar Health’s tech-driven growth contrasts with UnitedHealth’s massive scale and diversified revenue.
Investors are still underappreciating the potential for this healthcare company's growth.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Shares trade up 53% so far in 2026, but they are still underappreciated by investors.
Shares of health insurance company Oscar Health (NYSE:OSCR) fell 3.3% in the morning session after the company's Chief Financial Officer, Richard Blackley, sold $2.75 million in company stock, a move that can sometimes worry investors about a company's outlook.
Oscar Health (OSCR) has been in focus after the Centers for Medicare & Medicaid Services cut user fees for Affordable Care Act marketplaces, alongside first quarter results that included 147% net income growth and 52% revenue growth year over year. See our latest analysis for Oscar Health. The CMS fee cuts and strong first quarter figures have coincided with a sharp shift in sentiment, with Oscar Health posting a 37.71% 1 month share price return and a 59.77% 1 year total shareholder return...
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Oscar Health Inc. (NYSE:OSCR) is one of the 10 Stocks Dominating With Powerful Gains. Oscar Health climbed to a new five-year high on Monday, as investors resumed buying positions in its stock after the Centers for Medicare & Medicaid Services (CMS) formally lowered user fees for the Affordable Care Act (ACA) marketplaces. In intra-day trading, […]
Oscar Health stock hasn't looked back after reporting Q1 earnings that more than doubled from the year-ago quarter.
Oscar Health (NYSE:OSCR) has appointed Siddhartha Sankaran as Independent Chair of the Board. The company has introduced new affordable health insurance products in multiple U.S. regions. These developments reflect ongoing changes in leadership and product offerings beyond routine disclosures. Oscar Health operates in the U.S. health insurance sector, focusing on individual and family coverage supported by technology driven member services. The appointment of an Independent Chair can...
Oscar Health’s first quarter results prompted a positive market reaction as management delivered substantial improvements in profitability, even as revenue came in below consensus. CEO Mark Bertolini attributed the performance to disciplined expense management, robust membership growth, and the growing impact of artificial intelligence (AI) across operations. Notably, Oscar’s medical loss ratio improved sharply, and management highlighted the effectiveness of new technology-driven transparency t
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
